| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 21 | 2022 | 806 | 1.790 |
Why?
|
| Community Health Centers | 12 | 2023 | 113 | 1.620 |
Why?
|
| Endocrine Disruptors | 6 | 2009 | 27 | 1.540 |
Why?
|
| Coturnix | 8 | 2009 | 13 | 1.510 |
Why?
|
| Genital Neoplasms, Female | 6 | 2017 | 107 | 1.390 |
Why?
|
| Islam | 3 | 2019 | 34 | 1.390 |
Why?
|
| Melanoma | 14 | 2015 | 454 | 1.090 |
Why?
|
| Mammography | 3 | 2019 | 461 | 1.040 |
Why?
|
| Skin Neoplasms | 14 | 2015 | 541 | 0.990 |
Why?
|
| Reproduction | 4 | 2009 | 195 | 0.980 |
Why?
|
| Bursa of Fabricius | 3 | 2009 | 4 | 0.930 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 4 | 2007 | 6 | 0.890 |
Why?
|
| Trenbolone Acetate | 3 | 2007 | 3 | 0.870 |
Why?
|
| Patient-Centered Care | 7 | 2014 | 202 | 0.870 |
Why?
|
| Health Behavior | 6 | 2018 | 183 | 0.850 |
Why?
|
| Office Visits | 1 | 2022 | 44 | 0.830 |
Why?
|
| Female | 102 | 2024 | 44507 | 0.810 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 84 | 0.810 |
Why?
|
| Colinus | 4 | 2009 | 4 | 0.800 |
Why?
|
| Abortion, Induced | 4 | 2019 | 120 | 0.790 |
Why?
|
| Primary Health Care | 6 | 2022 | 339 | 0.720 |
Why?
|
| Self Care | 8 | 2019 | 164 | 0.720 |
Why?
|
| Diabetes Mellitus, Type 2 | 13 | 2023 | 1373 | 0.700 |
Why?
|
| Healthcare Disparities | 7 | 2015 | 370 | 0.690 |
Why?
|
| Patient Education as Topic | 13 | 2019 | 351 | 0.690 |
Why?
|
| Sexual Behavior, Animal | 3 | 2009 | 92 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2023 | 238 | 0.650 |
Why?
|
| Middle Aged | 66 | 2022 | 25017 | 0.650 |
Why?
|
| Humans | 121 | 2024 | 86601 | 0.640 |
Why?
|
| Intention | 2 | 2016 | 51 | 0.630 |
Why?
|
| Attitude of Health Personnel | 8 | 2022 | 636 | 0.630 |
Why?
|
| Soil Pollutants | 4 | 2010 | 7 | 0.620 |
Why?
|
| Adult | 61 | 2023 | 25640 | 0.610 |
Why?
|
| Sexual Maturation | 2 | 2007 | 35 | 0.600 |
Why?
|
| Denervation | 1 | 2016 | 34 | 0.590 |
Why?
|
| Environmental Pollutants | 5 | 2012 | 51 | 0.590 |
Why?
|
| Health Services Accessibility | 7 | 2021 | 394 | 0.580 |
Why?
|
| Arabs | 1 | 2016 | 17 | 0.580 |
Why?
|
| Patient Participation | 6 | 2012 | 216 | 0.570 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2008 | 275 | 0.570 |
Why?
|
| Aged | 48 | 2024 | 18402 | 0.560 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 2887 | 0.550 |
Why?
|
| Decision Making | 5 | 2012 | 642 | 0.540 |
Why?
|
| Placenta | 1 | 2016 | 175 | 0.520 |
Why?
|
| Male | 73 | 2024 | 40956 | 0.510 |
Why?
|
| Pregnancy, Tubal | 1 | 2014 | 4 | 0.510 |
Why?
|
| Androgen Antagonists | 2 | 2006 | 144 | 0.510 |
Why?
|
| Fallopian Tubes | 1 | 2014 | 41 | 0.500 |
Why?
|
| Triazines | 3 | 2009 | 53 | 0.490 |
Why?
|
| Attitude to Health | 5 | 2016 | 220 | 0.490 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2014 | 63 | 0.490 |
Why?
|
| Explosive Agents | 3 | 2009 | 4 | 0.470 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 57 | 0.470 |
Why?
|
| Toxicity Tests | 3 | 2010 | 13 | 0.460 |
Why?
|
| Lymph Node Excision | 6 | 2017 | 213 | 0.460 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2014 | 135 | 0.440 |
Why?
|
| Ovarian Neoplasms | 4 | 2017 | 744 | 0.440 |
Why?
|
| Interviews as Topic | 10 | 2019 | 319 | 0.430 |
Why?
|
| Surveys and Questionnaires | 14 | 2019 | 2501 | 0.420 |
Why?
|
| Physician-Patient Relations | 9 | 2016 | 610 | 0.420 |
Why?
|
| Depression | 3 | 2022 | 473 | 0.420 |
Why?
|
| Health Promotion | 3 | 2019 | 160 | 0.420 |
Why?
|
| Safety-net Providers | 3 | 2017 | 37 | 0.400 |
Why?
|
| Gonads | 2 | 2009 | 19 | 0.400 |
Why?
|
| Health Care Surveys | 5 | 2019 | 278 | 0.400 |
Why?
|
| Dinitrobenzenes | 2 | 2007 | 5 | 0.390 |
Why?
|
| Psychiatry | 2 | 2022 | 78 | 0.390 |
Why?
|
| Physicians | 6 | 2019 | 673 | 0.390 |
Why?
|
| Quality Assurance, Health Care | 5 | 2012 | 220 | 0.390 |
Why?
|
| Anxiety | 1 | 2013 | 287 | 0.380 |
Why?
|
| United States | 17 | 2023 | 6665 | 0.380 |
Why?
|
| Mass Screening | 7 | 2016 | 617 | 0.380 |
Why?
|
| Mexican Americans | 2 | 2014 | 63 | 0.380 |
Why?
|
| Pregnancy | 8 | 2019 | 2893 | 0.370 |
Why?
|
| Burnout, Professional | 2 | 2012 | 94 | 0.370 |
Why?
|
| Embryo, Nonmammalian | 4 | 2007 | 193 | 0.370 |
Why?
|
| Environmental Exposure | 6 | 2012 | 296 | 0.360 |
Why?
|
| Psychometrics | 4 | 2019 | 327 | 0.360 |
Why?
|
| Religion | 4 | 2018 | 87 | 0.360 |
Why?
|
| Morale | 2 | 2012 | 14 | 0.350 |
Why?
|
| Pentaerythritol Tetranitrate | 1 | 2009 | 1 | 0.350 |
Why?
|
| Adolescent | 31 | 2019 | 8979 | 0.340 |
Why?
|
| Hypothalamus | 1 | 2009 | 79 | 0.340 |
Why?
|
| Fetal Development | 1 | 2009 | 30 | 0.340 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 103 | 0.340 |
Why?
|
| Social Support | 5 | 2019 | 193 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 1313 | 0.330 |
Why?
|
| Australia | 7 | 2017 | 99 | 0.320 |
Why?
|
| Personnel Management | 1 | 2008 | 7 | 0.320 |
Why?
|
| Vasodilator Agents | 1 | 2009 | 152 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 1169 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2012 | 1961 | 0.320 |
Why?
|
| Copulation | 1 | 2007 | 4 | 0.320 |
Why?
|
| Carcinoma | 3 | 2008 | 436 | 0.320 |
Why?
|
| Estradiol | 1 | 2009 | 252 | 0.320 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 135 | 0.310 |
Why?
|
| Models, Animal | 1 | 2009 | 263 | 0.310 |
Why?
|
| Depressive Disorder | 2 | 2013 | 218 | 0.310 |
Why?
|
| Patient Care Team | 2 | 2014 | 280 | 0.310 |
Why?
|
| Community Health Services | 3 | 2014 | 80 | 0.310 |
Why?
|
| Biomarkers, Tumor | 3 | 2005 | 1464 | 0.310 |
Why?
|
| Anabolic Agents | 1 | 2007 | 3 | 0.300 |
Why?
|
| Spirituality | 2 | 2013 | 87 | 0.300 |
Why?
|
| Medicaid | 2 | 2020 | 217 | 0.290 |
Why?
|
| Occupational Health Services | 1 | 2006 | 4 | 0.290 |
Why?
|
| Endometrial Neoplasms | 3 | 2014 | 193 | 0.290 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 66 | 0.290 |
Why?
|
| Aged, 80 and over | 21 | 2015 | 6501 | 0.290 |
Why?
|
| Adaptation, Psychological | 3 | 2019 | 157 | 0.290 |
Why?
|
| Contraception | 3 | 2019 | 88 | 0.290 |
Why?
|
| Chicago | 15 | 2018 | 1379 | 0.290 |
Why?
|
| Educational Status | 3 | 2013 | 188 | 0.290 |
Why?
|
| Lymphatic Metastasis | 8 | 2014 | 481 | 0.290 |
Why?
|
| Workplace | 1 | 2006 | 27 | 0.290 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 153 | 0.280 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 177 | 0.280 |
Why?
|
| Animals | 22 | 2012 | 26581 | 0.280 |
Why?
|
| Trinitrotoluene | 3 | 2012 | 3 | 0.280 |
Why?
|
| Pilot Projects | 7 | 2022 | 839 | 0.280 |
Why?
|
| Neoplasm Staging | 9 | 2015 | 1937 | 0.270 |
Why?
|
| Motivational Interviewing | 2 | 2016 | 17 | 0.270 |
Why?
|
| Health Education | 1 | 2006 | 100 | 0.270 |
Why?
|
| Lymph Nodes | 5 | 2014 | 530 | 0.270 |
Why?
|
| Complementary Therapies | 1 | 2006 | 54 | 0.270 |
Why?
|
| Mortality | 2 | 2003 | 149 | 0.270 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 239 | 0.260 |
Why?
|
| Program Evaluation | 6 | 2014 | 297 | 0.260 |
Why?
|
| Language | 2 | 2019 | 151 | 0.260 |
Why?
|
| Occupations | 1 | 2005 | 26 | 0.260 |
Why?
|
| Religion and Medicine | 3 | 2016 | 122 | 0.260 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 392 | 0.260 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 48 | 0.260 |
Why?
|
| Quality Improvement | 5 | 2016 | 428 | 0.250 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2014 | 16 | 0.250 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 1621 | 0.250 |
Why?
|
| Models, Theoretical | 2 | 2007 | 482 | 0.250 |
Why?
|
| Lymphedema | 2 | 2017 | 77 | 0.250 |
Why?
|
| Health Personnel | 3 | 2017 | 202 | 0.250 |
Why?
|
| Weight Loss | 4 | 2006 | 229 | 0.250 |
Why?
|
| Morphogenesis | 1 | 2005 | 192 | 0.240 |
Why?
|
| Catholicism | 2 | 2015 | 43 | 0.240 |
Why?
|
| Qualitative Research | 5 | 2016 | 256 | 0.240 |
Why?
|
| Lizards | 4 | 2012 | 24 | 0.240 |
Why?
|
| Lead | 3 | 2010 | 26 | 0.240 |
Why?
|
| Ascitic Fluid | 1 | 2003 | 37 | 0.240 |
Why?
|
| Patient Preference | 2 | 2016 | 105 | 0.240 |
Why?
|
| Obesity | 6 | 2013 | 963 | 0.230 |
Why?
|
| Frail Elderly | 1 | 2024 | 71 | 0.230 |
Why?
|
| Allied Health Personnel | 2 | 2001 | 19 | 0.230 |
Why?
|
| Frailty | 1 | 2024 | 58 | 0.220 |
Why?
|
| Body Weight | 6 | 2010 | 459 | 0.210 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 311 | 0.210 |
Why?
|
| Follow-Up Studies | 11 | 2015 | 3636 | 0.210 |
Why?
|
| Family | 3 | 2015 | 311 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 1041 | 0.210 |
Why?
|
| Community-Based Participatory Research | 2 | 2019 | 36 | 0.200 |
Why?
|
| Mental Health Services | 1 | 2021 | 48 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2013 | 508 | 0.200 |
Why?
|
| Overweight | 3 | 2011 | 118 | 0.200 |
Why?
|
| Young Adult | 14 | 2016 | 5974 | 0.200 |
Why?
|
| Neoplasms | 4 | 2008 | 2897 | 0.200 |
Why?
|
| Behavior Therapy | 2 | 2011 | 75 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.190 |
Why?
|
| Rural Health Services | 2 | 2014 | 13 | 0.190 |
Why?
|
| Child | 19 | 2019 | 6926 | 0.190 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.190 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 426 | 0.190 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 22 | 0.190 |
Why?
|
| Health Services Needs and Demand | 2 | 2019 | 102 | 0.180 |
Why?
|
| Social Class | 8 | 2013 | 127 | 0.180 |
Why?
|
| Insurance Coverage | 3 | 2019 | 115 | 0.180 |
Why?
|
| Midwestern United States | 6 | 2019 | 76 | 0.180 |
Why?
|
| Organ Size | 4 | 2012 | 364 | 0.180 |
Why?
|
| Respite Care | 1 | 2019 | 9 | 0.180 |
Why?
|
| Prejudice | 2 | 2010 | 49 | 0.180 |
Why?
|
| Self-Management | 1 | 2019 | 29 | 0.180 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 30 | 0.180 |
Why?
|
| Job Satisfaction | 2 | 2012 | 73 | 0.180 |
Why?
|
| State Health Plans | 1 | 2019 | 14 | 0.180 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 454 | 0.170 |
Why?
|
| Disabled Children | 1 | 2019 | 43 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2705 | 0.170 |
Why?
|
| Time Factors | 8 | 2017 | 5209 | 0.170 |
Why?
|
| Survival Rate | 9 | 2015 | 1860 | 0.170 |
Why?
|
| Vulvar Neoplasms | 2 | 2017 | 20 | 0.170 |
Why?
|
| Blood Glucose | 2 | 2021 | 873 | 0.170 |
Why?
|
| Self Concept | 1 | 2019 | 133 | 0.160 |
Why?
|
| Aftercare | 1 | 2019 | 85 | 0.160 |
Why?
|
| Insecticides | 3 | 2007 | 27 | 0.160 |
Why?
|
| Vaginal Neoplasms | 2 | 2017 | 83 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 257 | 0.160 |
Why?
|
| Spleen | 3 | 2009 | 430 | 0.160 |
Why?
|
| Prospective Studies | 10 | 2023 | 4210 | 0.160 |
Why?
|
| Focus Groups | 6 | 2018 | 155 | 0.160 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 169 | 0.150 |
Why?
|
| Internet | 2 | 2012 | 312 | 0.150 |
Why?
|
| Leukocytes | 3 | 2010 | 202 | 0.150 |
Why?
|
| Exercise | 5 | 2024 | 315 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2017 | 59 | 0.150 |
Why?
|
| Prognosis | 9 | 2015 | 3674 | 0.150 |
Why?
|
| Ovum | 2 | 2007 | 58 | 0.150 |
Why?
|
| Forecasting | 6 | 2008 | 304 | 0.150 |
Why?
|
| Risk Factors | 8 | 2017 | 5416 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 74 | 0.140 |
Why?
|
| Professional-Patient Relations | 2 | 2014 | 53 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 21 | 0.140 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 32 | 0.140 |
Why?
|
| Feasibility Studies | 5 | 2019 | 751 | 0.140 |
Why?
|
| Chronic Disease | 3 | 2016 | 970 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2016 | 71 | 0.140 |
Why?
|
| Child, Preschool | 10 | 2019 | 3611 | 0.140 |
Why?
|
| Referral and Consultation | 3 | 2006 | 326 | 0.140 |
Why?
|
| Parents | 2 | 2010 | 272 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 394 | 0.140 |
Why?
|
| Quality of Health Care | 2 | 2011 | 380 | 0.140 |
Why?
|
| Syndrome | 1 | 2016 | 446 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 763 | 0.140 |
Why?
|
| Victoria | 2 | 2006 | 5 | 0.140 |
Why?
|
| Models, Organizational | 2 | 2013 | 46 | 0.140 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 18 | 0.130 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 378 | 0.130 |
Why?
|
| Wales | 7 | 2008 | 10 | 0.130 |
Why?
|
| Incidence | 6 | 2017 | 1576 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2009 | 684 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2016 | 129 | 0.130 |
Why?
|
| Health Status | 2 | 2014 | 360 | 0.130 |
Why?
|
| Program Development | 3 | 2014 | 124 | 0.130 |
Why?
|
| England | 7 | 2008 | 41 | 0.130 |
Why?
|
| Practice Management, Medical | 1 | 2014 | 24 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 145 | 0.130 |
Why?
|
| Gynecology | 1 | 2016 | 124 | 0.120 |
Why?
|
| Feedback | 1 | 2015 | 133 | 0.120 |
Why?
|
| Cultural Competency | 1 | 2014 | 21 | 0.120 |
Why?
|
| Diet | 3 | 2012 | 443 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 552 | 0.120 |
Why?
|
| Scalp | 1 | 2014 | 72 | 0.120 |
Why?
|
| Edema | 1 | 2014 | 71 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2013 | 52 | 0.120 |
Why?
|
| Dermoscopy | 1 | 2013 | 5 | 0.120 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2013 | 4 | 0.120 |
Why?
|
| Age Factors | 5 | 2007 | 1849 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 104 | 0.120 |
Why?
|
| Patient Handoff | 1 | 2015 | 93 | 0.120 |
Why?
|
| Environmental Monitoring | 2 | 2012 | 71 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 581 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2012 | 567 | 0.110 |
Why?
|
| Disease Management | 3 | 2014 | 327 | 0.110 |
Why?
|
| Personnel Turnover | 1 | 2013 | 7 | 0.110 |
Why?
|
| No-Observed-Adverse-Effect Level | 2 | 2010 | 2 | 0.110 |
Why?
|
| Malaria | 1 | 2012 | 23 | 0.110 |
Why?
|
| Europe | 2 | 2003 | 309 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2016 | 359 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 268 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2004 | 782 | 0.110 |
Why?
|
| Peer Group | 1 | 2012 | 72 | 0.100 |
Why?
|
| Life Style | 3 | 2016 | 189 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 302 | 0.100 |
Why?
|
| Standard of Care | 1 | 2012 | 78 | 0.100 |
Why?
|
| Infant | 7 | 2019 | 3045 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 158 | 0.100 |
Why?
|
| Urodela | 2 | 2009 | 18 | 0.100 |
Why?
|
| Trust | 1 | 2012 | 95 | 0.100 |
Why?
|
| Quality of Life | 2 | 2023 | 1583 | 0.100 |
Why?
|
| Professional Role | 2 | 2011 | 41 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 1239 | 0.100 |
Why?
|
| Urban Health Services | 2 | 2010 | 45 | 0.100 |
Why?
|
| Residence Characteristics | 4 | 2007 | 197 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2013 | 329 | 0.100 |
Why?
|
| Diet, Reducing | 2 | 2006 | 31 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 484 | 0.100 |
Why?
|
| Disease Progression | 2 | 2013 | 1531 | 0.100 |
Why?
|
| Family Health | 1 | 2011 | 162 | 0.100 |
Why?
|
| Child Health Services | 1 | 2011 | 49 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2017 | 48 | 0.090 |
Why?
|
| Urban Population | 5 | 2007 | 213 | 0.090 |
Why?
|
| Firearms | 2 | 2010 | 48 | 0.090 |
Why?
|
| Schools | 1 | 2011 | 71 | 0.090 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2017 | 62 | 0.090 |
Why?
|
| Coronary Disease | 1 | 1991 | 261 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 102 | 0.090 |
Why?
|
| Azocines | 1 | 2009 | 3 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1169 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2013 | 1753 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1034 | 0.090 |
Why?
|
| General Surgery | 1 | 2012 | 228 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2010 | 220 | 0.090 |
Why?
|
| 1-Octanol | 1 | 2009 | 1 | 0.090 |
Why?
|
| Body Weights and Measures | 1 | 2009 | 27 | 0.090 |
Why?
|
| Biodegradation, Environmental | 1 | 2009 | 17 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 696 | 0.090 |
Why?
|
| Sex Ratio | 1 | 2009 | 22 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2013 | 628 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 2357 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 290 | 0.080 |
Why?
|
| Vietnam | 1 | 2008 | 14 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 364 | 0.080 |
Why?
|
| Malaysia | 1 | 2008 | 12 | 0.080 |
Why?
|
| Indonesia | 1 | 2008 | 11 | 0.080 |
Why?
|
| Wrist Joint | 1 | 2008 | 23 | 0.080 |
Why?
|
| Philippines | 1 | 2008 | 23 | 0.080 |
Why?
|
| Human papillomavirus 18 | 1 | 2008 | 16 | 0.080 |
Why?
|
| Thailand | 1 | 2008 | 66 | 0.080 |
Why?
|
| Papanicolaou Test | 1 | 2008 | 38 | 0.080 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 38 | 0.080 |
Why?
|
| Solubility | 1 | 2009 | 177 | 0.080 |
Why?
|
| Mercury | 1 | 1988 | 8 | 0.080 |
Why?
|
| Employee Incentive Plans | 1 | 2008 | 4 | 0.080 |
Why?
|
| Personnel Loyalty | 1 | 2008 | 4 | 0.080 |
Why?
|
| Health Facility Administrators | 1 | 2008 | 15 | 0.080 |
Why?
|
| Vaginal Smears | 1 | 2008 | 68 | 0.080 |
Why?
|
| Toluene | 1 | 2008 | 5 | 0.080 |
Why?
|
| Antirheumatic Agents | 1 | 2008 | 54 | 0.080 |
Why?
|
| Pregnancy, Unplanned | 2 | 2019 | 18 | 0.080 |
Why?
|
| Nail Diseases | 1 | 2007 | 5 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2015 | 1804 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 1019 | 0.080 |
Why?
|
| Laryngeal Neoplasms | 1 | 2008 | 89 | 0.080 |
Why?
|
| Professional Autonomy | 1 | 2008 | 41 | 0.080 |
Why?
|
| Sex Differentiation | 1 | 2007 | 9 | 0.080 |
Why?
|
| CA-125 Antigen | 2 | 2005 | 22 | 0.080 |
Why?
|
| Staff Development | 1 | 2008 | 21 | 0.080 |
Why?
|
| Survival Analysis | 5 | 2008 | 1538 | 0.080 |
Why?
|
| Eggs | 1 | 2007 | 12 | 0.080 |
Why?
|
| Sociology, Medical | 1 | 2007 | 4 | 0.080 |
Why?
|
| Hypertension | 1 | 2016 | 1141 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2008 | 58 | 0.080 |
Why?
|
| Endocrine System | 1 | 2007 | 17 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2007 | 31 | 0.080 |
Why?
|
| Body Mass Index | 4 | 2017 | 770 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2014 | 8475 | 0.080 |
Why?
|
| Birds | 2 | 2007 | 157 | 0.070 |
Why?
|
| Fertility | 1 | 2007 | 115 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 166 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2207 | 0.070 |
Why?
|
| Psychology, Educational | 1 | 2006 | 2 | 0.070 |
Why?
|
| Teaching Materials | 1 | 2006 | 12 | 0.070 |
Why?
|
| United Kingdom | 2 | 2003 | 164 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 128 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 1052 | 0.070 |
Why?
|
| Electronic Mail | 1 | 2006 | 14 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 1204 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2007 | 151 | 0.070 |
Why?
|
| Vaccination | 1 | 2008 | 254 | 0.070 |
Why?
|
| Models, Educational | 1 | 2006 | 50 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2014 | 2767 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2006 | 27 | 0.070 |
Why?
|
| Glioma | 1 | 2008 | 285 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2006 | 74 | 0.070 |
Why?
|
| DDT | 1 | 2005 | 4 | 0.070 |
Why?
|
| Documentation | 1 | 2006 | 98 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1219 | 0.070 |
Why?
|
| Registries | 3 | 2008 | 702 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 339 | 0.070 |
Why?
|
| Skeleton | 1 | 2005 | 23 | 0.070 |
Why?
|
| Sexual Behavior | 1 | 2008 | 302 | 0.070 |
Why?
|
| Fear | 1 | 2006 | 78 | 0.070 |
Why?
|
| Models, Psychological | 1 | 2006 | 157 | 0.070 |
Why?
|
| Demography | 1 | 2006 | 177 | 0.070 |
Why?
|
| Endocrine Glands | 1 | 2005 | 13 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 1185 | 0.070 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 44 | 0.070 |
Why?
|
| Lethal Dose 50 | 3 | 2009 | 8 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2005 | 144 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2006 | 85 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 306 | 0.060 |
Why?
|
| Marital Status | 1 | 2005 | 40 | 0.060 |
Why?
|
| Mexico | 1 | 2005 | 67 | 0.060 |
Why?
|
| Oregon | 2 | 2014 | 26 | 0.060 |
Why?
|
| Colorado | 2 | 2014 | 35 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2005 | 270 | 0.060 |
Why?
|
| Income | 1 | 2005 | 75 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2007 | 373 | 0.060 |
Why?
|
| Androgens | 1 | 2005 | 167 | 0.060 |
Why?
|
| Oncology Service, Hospital | 1 | 2004 | 6 | 0.060 |
Why?
|
| Animals, Newborn | 1 | 2006 | 510 | 0.060 |
Why?
|
| Cell-Free System | 1 | 2004 | 51 | 0.060 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2004 | 30 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2003 | 938 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 85 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 167 | 0.060 |
Why?
|
| Estrogens | 1 | 2005 | 200 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2004 | 27 | 0.060 |
Why?
|
| Cervix Uteri | 1 | 2004 | 65 | 0.060 |
Why?
|
| Peritoneum | 1 | 2004 | 57 | 0.060 |
Why?
|
| Proteomics | 1 | 2005 | 212 | 0.060 |
Why?
|
| Cystadenoma, Serous | 1 | 2003 | 15 | 0.060 |
Why?
|
| Health Services Research | 2 | 2014 | 136 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2004 | 104 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 2261 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2024 | 80 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2006 | 324 | 0.060 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2003 | 43 | 0.060 |
Why?
|
| SEER Program | 1 | 2003 | 184 | 0.060 |
Why?
|
| Communication | 1 | 2006 | 440 | 0.060 |
Why?
|
| Rats | 1 | 2009 | 3990 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 162 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1685 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2003 | 322 | 0.050 |
Why?
|
| Pediatrics | 2 | 1999 | 344 | 0.050 |
Why?
|
| Tape Recording | 2 | 2012 | 19 | 0.050 |
Why?
|
| Rheumatology | 1 | 2001 | 28 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2001 | 34 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 427 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2023 | 237 | 0.050 |
Why?
|
| Linear Models | 2 | 2014 | 421 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2004 | 712 | 0.050 |
Why?
|
| Women's Health Services | 1 | 2001 | 15 | 0.050 |
Why?
|
| Christianity | 1 | 2001 | 36 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 352 | 0.050 |
Why?
|
| Insurance, Health | 2 | 2015 | 160 | 0.050 |
Why?
|
| Poverty | 2 | 2019 | 173 | 0.050 |
Why?
|
| Dialysis Solutions | 1 | 2000 | 7 | 0.050 |
Why?
|
| Chylous Ascites | 1 | 2000 | 9 | 0.050 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2000 | 16 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2232 | 0.050 |
Why?
|
| Smoking | 3 | 2008 | 609 | 0.050 |
Why?
|
| Public Health | 1 | 2021 | 129 | 0.050 |
Why?
|
| Spermatozoa | 2 | 2012 | 62 | 0.050 |
Why?
|
| Peritoneal Dialysis | 1 | 2000 | 32 | 0.050 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 30 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 645 | 0.050 |
Why?
|
| Photography | 1 | 2019 | 37 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2003 | 2378 | 0.040 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 20 | 0.040 |
Why?
|
| Illinois | 1 | 2001 | 462 | 0.040 |
Why?
|
| Proteins | 1 | 2005 | 777 | 0.040 |
Why?
|
| Testosterone | 2 | 2012 | 271 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1999 | 80 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 111 | 0.040 |
Why?
|
| Superoxides | 1 | 1998 | 73 | 0.040 |
Why?
|
| NADPH Oxidases | 1 | 1998 | 81 | 0.040 |
Why?
|
| Plethysmography, Impedance | 1 | 2017 | 4 | 0.040 |
Why?
|
| Microglia | 1 | 1998 | 102 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 860 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2015 | 1143 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2017 | 81 | 0.040 |
Why?
|
| Fertility Preservation | 1 | 2017 | 17 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 2216 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 72 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2016 | 20 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 24 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2017 | 84 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2016 | 55 | 0.040 |
Why?
|
| Women's Health | 1 | 1997 | 100 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2017 | 116 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2016 | 81 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2017 | 303 | 0.040 |
Why?
|
| Thigh | 1 | 1996 | 38 | 0.030 |
Why?
|
| Perineum | 1 | 1996 | 35 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2016 | 118 | 0.030 |
Why?
|
| Developing Countries | 1 | 2016 | 71 | 0.030 |
Why?
|
| Synovitis | 2 | 2008 | 14 | 0.030 |
Why?
|
| Patient Navigation | 1 | 2015 | 12 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 357 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 288 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2017 | 328 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 1990 | 0.030 |
Why?
|
| New South Wales | 1 | 2014 | 3 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 266 | 0.030 |
Why?
|
| Idaho | 1 | 2014 | 7 | 0.030 |
Why?
|
| Sex Factors | 2 | 2011 | 1054 | 0.030 |
Why?
|
| Massachusetts | 1 | 2014 | 33 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2014 | 27 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1999 | 375 | 0.030 |
Why?
|
| Global Health | 1 | 2016 | 193 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 75 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1996 | 172 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 2436 | 0.030 |
Why?
|
| Psychology, Child | 1 | 1994 | 12 | 0.030 |
Why?
|
| Education, Continuing | 1 | 1994 | 11 | 0.030 |
Why?
|
| Internal-External Control | 1 | 1994 | 44 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2013 | 33 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2013 | 23 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 30 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 567 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 307 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 52 | 0.030 |
Why?
|
| Leg | 1 | 2014 | 137 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 1993 | 62 | 0.030 |
Why?
|
| Joint Diseases | 1 | 1993 | 49 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 153 | 0.030 |
Why?
|
| Plasmodium | 1 | 2012 | 10 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2012 | 14 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 42 | 0.030 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2013 | 57 | 0.030 |
Why?
|
| Lymphoscintigraphy | 1 | 2012 | 3 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 1996 | 449 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2013 | 219 | 0.030 |
Why?
|
| California | 1 | 2012 | 138 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2012 | 9 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1720 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 487 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 999 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2011 | 28 | 0.020 |
Why?
|
| Systems Integration | 1 | 2011 | 35 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2004 | 695 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1991 | 161 | 0.020 |
Why?
|
| Diabetes Complications | 2 | 2007 | 207 | 0.020 |
Why?
|
| Salamandridae | 1 | 2010 | 2 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2010 | 23 | 0.020 |
Why?
|
| Soil | 1 | 2010 | 31 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2012 | 196 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 535 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 174 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 179 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 857 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2010 | 255 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 92 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 636 | 0.020 |
Why?
|
| Methylmercury Compounds | 1 | 1988 | 3 | 0.020 |
Why?
|
| Fish Products | 1 | 1988 | 3 | 0.020 |
Why?
|
| Toes | 1 | 2007 | 14 | 0.020 |
Why?
|
| Mathematics | 1 | 1988 | 190 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 11 | 0.020 |
Why?
|
| Hematology | 1 | 2008 | 29 | 0.020 |
Why?
|
| Helping Behavior | 1 | 2007 | 8 | 0.020 |
Why?
|
| Medical Staff | 1 | 2007 | 10 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2007 | 20 | 0.020 |
Why?
|
| Color | 1 | 2008 | 81 | 0.020 |
Why?
|
| Nursing Staff | 1 | 2007 | 10 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 2007 | 28 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1208 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2007 | 83 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2007 | 25 | 0.020 |
Why?
|
| Nevus, Pigmented | 1 | 2007 | 49 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2007 | 32 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 379 | 0.020 |
Why?
|
| Fingers | 1 | 2007 | 68 | 0.020 |
Why?
|
| Individuality | 1 | 1988 | 109 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 1229 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2008 | 312 | 0.020 |
Why?
|
| Self-Help Groups | 1 | 2007 | 14 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 594 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 227 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 722 | 0.020 |
Why?
|
| Songbirds | 1 | 2007 | 83 | 0.020 |
Why?
|
| Leadership | 1 | 2007 | 134 | 0.020 |
Why?
|
| Minority Groups | 1 | 2007 | 137 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 27 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2005 | 81 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1988 | 912 | 0.020 |
Why?
|
| Methoxychlor | 1 | 2005 | 1 | 0.020 |
Why?
|
| Water Supply | 1 | 1985 | 60 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2005 | 4 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2006 | 98 | 0.020 |
Why?
|
| Lipase | 1 | 2005 | 22 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 327 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2005 | 69 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2004 | 50 | 0.020 |
Why?
|
| Diabetic Nephropathies | 2 | 2000 | 248 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 218 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 220 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 674 | 0.020 |
Why?
|
| Seasons | 1 | 1985 | 223 | 0.020 |
Why?
|
| Carboplatin | 1 | 2005 | 286 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2005 | 256 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2005 | 460 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1565 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 451 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 460 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1985 | 266 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 7988 | 0.010 |
Why?
|
| Tenosynovitis | 1 | 2001 | 7 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2062 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 776 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3030 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1823 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 204 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2001 | 181 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 669 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 2261 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 1998 | 33 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 68 | 0.010 |
Why?
|
| Free Radicals | 1 | 1998 | 73 | 0.010 |
Why?
|
| Sheep | 1 | 1998 | 239 | 0.010 |
Why?
|
| Body Constitution | 1 | 1997 | 26 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 376 | 0.010 |
Why?
|
| Waiting Lists | 1 | 1997 | 175 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1998 | 306 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2000 | 509 | 0.010 |
Why?
|
| Vagina | 1 | 1996 | 161 | 0.010 |
Why?
|
| Curriculum | 1 | 1999 | 539 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 1996 | 241 | 0.010 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 71 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2818 | 0.010 |
Why?
|
| Albuminuria | 1 | 1993 | 153 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 1993 | 87 | 0.010 |
Why?
|
| Research | 1 | 1994 | 253 | 0.010 |
Why?
|